WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H412506
CAS#: 104145-95-1 (free base)
Description: Cefditoren (free base) is a broad-spectrum antibiotic, taken by mouth to treat pneumonia and other infections.
Hodoodo Cat#: H412506
Name: Cefditoren (free base)
CAS#: 104145-95-1 (free base)
Chemical Formula: C19H18N6O5S3
Exact Mass: 506.05
Molecular Weight: 506.570
Elemental Analysis: C, 45.05; H, 3.58; N, 16.59; O, 15.79; S, 18.99
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 104146-53-4 (sodium) 104145-95-1 (free base) 117467-28-4 (pivoxil) 442852-27-9 (tosylate) 442852-31-5 (oxalate) 442852-33-7 (sulfate) 1448435-17-3 (HCl) 442852-29-1 (mesylate)
Synonym: Cefditoren; UNII-81QS09V3YW
IUPAC/Chemical Name: (6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((Z)-2-(4-methylthiazol-5-yl)vinyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChi Key: KMIPKYQIOVAHOP-YLGJWRNMSA-N
InChi Code: InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1
SMILES Code: CO/N=C(c1nc(N)sc1)\C(N[C@H]2[C@H]3SCC(/C=C\c4c(C)ncs4)=C(C(O)=O)N3C2=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 506.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Giménez MJ, Aguilar L, Granizo JJ. Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults. Multidiscip Respir Med. 2018 Nov 2;13:40. doi: 10.1186/s40248-018-0152-5. PMID: 30410757; PMCID: PMC6214181.
2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Cefditoren. 2018 Oct 31. PMID: 30000384.
3: Sánchez Artola B, Barberán J. Cefditoreno: una realidad para el tratamiento de las infecciones comunitarias [Cefditoren: a reality for the treatment of community infections]. Rev Esp Quimioter. 2017 Dec;30(6):407-412. Spanish. Epub 2017 Dec 4. PMID: 29199418.
4: Darkes MJ, Plosker GL. Cefditoren pivoxil. Drugs. 2002;62(2):319-36; discussion 337-8. doi: 10.2165/00003495-200262020-00006. PMID: 11817976.
5: Soriano F, Giménez MJ, Aguilar L. Cefditoren in upper and lower community- acquired respiratory tract infections. Drug Des Devel Ther. 2011 Feb 9;5:85-94. doi: 10.2147/DDDT.S9499. PMID: 21340042; PMCID: PMC3038999.
6: Balbisi EA. Cefditoren, a new aminothiazolyl cephalosporin. Pharmacotherapy. 2002 Oct;22(10):1278-93. doi: 10.1592/phco.22.15.1278.33481. PMID: 12389878.
7: Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC, Fuchs PC. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis. 2001 Sep-Oct;41(1-2):1-14. doi: 10.1016/s0732-8893(01)00274-7. PMID: 11687308.
8: Guay DR. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther. 2001 Dec;23(12):1924-37; discussion 1923. doi: 10.1016/s0149-2918(01)80147-8. PMID: 11813929.
9: Di Marco F, Braido F, Santus P, Scichilone N, Blasi F. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage. Eur Rev Med Pharmacol Sci. 2014;18(3):321-32. PMID: 24563430.
10: Barberán J, Mensa J. Cefditoren en las infecciones de vías respiratorias bajas adquiridas en la comunidad [Cefditoren and community-acquired lower respiratory tract infections (corrected)]. Rev Esp Quimioter. 2009 Sep;22(3):144-50. Spanish. Erratum in: Rev Esp Quimioter. 2011 Mar;24(1):56. PMID: 19662548.
